S&P 500

5.728,64

0,18%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics Inc (CYCN) Notícias

CYCN

Cyclerion Therapeutics (CYCN)

Cyclerion Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:CYCN

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
07/08/2024	17:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CYCN	Cyclerion Therapeutics Inc
07/08/2024	08:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
07/08/2024	08:00	GlobeNewswire Inc.	Regina Graul, Ph.D., Promoted to Chief Executive Officer	NASDAQ:CYCN	Cyclerion Therapeutics Inc
07/08/2024	07:45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
11/12/2023	19:09	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CYCN	Cyclerion Therapeutics Inc
07/12/2023	18:05	Edgar (US Regulatory)	Form 3/A - Initial statement of beneficial ownership of securities: [Amend]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
04/12/2023	10:00	GlobeNewswire Inc.	Cyclerion Appoints Regina Graul, Ph.D., as President	NASDAQ:CYCN	Cyclerion Therapeutics Inc
30/11/2023	20:16	GlobeNewswire Inc.	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	NASDAQ:CYCN	Cyclerion Therapeutics Inc
31/07/2023	08:00	GlobeNewswire Inc.	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	NASDAQ:CYCN	Cyclerion Therapeutics Inc
20/06/2023	17:56	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
09/06/2023	18:24	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
01/06/2023	17:08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
01/06/2023	17:00	GlobeNewswire Inc.	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CYCN	Cyclerion Therapeutics Inc
23/05/2023	17:00	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
15/05/2023	14:00	GlobeNewswire Inc.	Cyclerion Announces Reverse Stock Split	NASDAQ:CYCN	Cyclerion Therapeutics Inc
12/05/2023	07:05	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
11/05/2023	19:00	GlobeNewswire Inc.	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	NASDAQ:CYCN	Cyclerion Therapeutics Inc
11/05/2023	19:00	GlobeNewswire Inc.	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	NASDAQ:CYCN	Cyclerion Therapeutics Inc
03/04/2023	08:30	GlobeNewswire Inc.	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement	NASDAQ:CYCN	Cyclerion Therapeutics Inc
27/03/2023	08:00	GlobeNewswire Inc.	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases	NASDAQ:CYCN	Cyclerion Therapeutics Inc
22/03/2023	18:01	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
22/03/2023	17:40	GlobeNewswire Inc.	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results	NASDAQ:CYCN	Cyclerion Therapeutics Inc
09/02/2023	12:02	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
13/01/2023	18:31	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
22/11/2022	09:00	GlobeNewswire Inc.	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company	NASDAQ:CYCN	Cyclerion Therapeutics Inc
21/10/2022	18:14	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
06/10/2022	09:00	GlobeNewswire Inc.	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy	NASDAQ:CYCN	Cyclerion Therapeutics Inc
10/08/2022	17:46	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
09/08/2022	17:00	GlobeNewswire Inc.	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results	NASDAQ:CYCN	Cyclerion Therapeutics Inc
28/07/2022	08:00	GlobeNewswire Inc.	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)	NASDAQ:CYCN	Cyclerion Therapeutics Inc